Incremental Value of CSF Biomarkers in Clinically Diagnosed AD and Non-AD Dementia.

Fiche publication

Date publication

janvier 2020

Journal

Frontiers in neurology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GILLERY Philippe , Dr OUDART Jean-Baptiste

Tous les auteurs :
Oudart JB, Djerada Z, Nonnonhou V, Badr S, Bertholon LA, Dammak A, Jaidi Y, Novella JL, Pallet N, Gillery P, Mahmoudi R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32670183

Résumé

Cerebrospinal fluid (CSF) biomarkers are used to diagnose Alzheimer disease (AD), especially in atypical clinical presentations. No consensus currently exists regarding cut-off values. This study aimed, firstly, to define optimal cut-off values for CSF biomarkers, and secondly, to investigate the most relevant diagnostic strategy for AD based on CSF biomarker combinations. A total of 380 patients were prospectively included: 140 with AD, 240 with various neurological diagnoses (non-AD). CSF biomarkers were measured using ELISA. Univariate and multivariate analyses were performed using random forest and logistic regression approaches. Univariate receiver operating curve curves analysis of T-Tau, P-Tau, Aβ, Aβ concentrations, and Aβ/Aβ ratio levels showed AD cut-off values of ≥355, ≥57, ≤706, ≥10,854, and ≤0.059 ng/L, respectively. Multivariate analysis using random forest and logistic regression found that the algorithm based on P-Tau, Aβ concentrations and Aβ/Aβ ratio yielded the best discrimination between AD and non-AD populations. The cross-validation technique of the final model showed a mean accuracy of 0.85 and a mean AUC of 0.89. This study confirms that the Aβ/Aβ ratio was more useful than the Aβ concentration in discriminating AD from non-AD populations in daily practice. These results indicate that the Aβ/Aβ ratio should be assessed in all cases, independently of Aβ concentrations.